Daval International has reported positive results from a Phase II study, evaluating the safety and tolerability of Aimspro as a monotherapy to treat patients with late-stage established diffuse cutaneous systemic sclerosis.

Twenty paitents were enrolled in the double-blind, randomised and placebo-controlled study. They were given either Aimspro or placebo, 4.5mg/ml subcutaneously, twice weekly for 26 weeks.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The primary endpoint was to assess the safety and tolerability of the drug through the 26-week period.

The secondary measures included investigating the efficacy of Aimspro as a therapeutic agent for scleroderma using inter alia the Scleroderma Health Assessment Questionnaire, the Modified Rodnan Skin Score, the Scleroderma UK Functional Score, the Patient and Physician Global Assessment, the SF-36 and the MRC Sum Score.

At the end of the study, Aimspro was found to be a safe and well-tolerated medication when administered to systemic sclerosis patients at a late-stage of the disease.

Aimspro treatment combines the benefits of polyclonal antibody technology with polypeptide components.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now